SCI Abstract

search
+
The length of price&reimbursement negotiation procedures in Italy in the period 2021-2023 was independent from the price of medicines
Introduzione La durata delle procedure di negoziazione di prezzo e rimborso dei nuovi medicinali è considerata uno dei ...
What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe
For patients in Europe, access to – and the availability of – innovative medicines vary widely across the d...
Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)
Introduction Activated phosphoinositide 3-kinase delta syndrome (APDS) is a hereditary (autosomal dominant) ultra-rare ...
Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
Introduction Respiratory syncytial virus (RSV) is one of the global leading causes of respiratory infections during chi...
Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices
Introduzione Il concetto di sostenibilità si riferisce alla capacità di mantenere e preservare le risorse naturali, soc...
Cost of illness of Heart Valve Diseases (HVDs): A real-world analysis in Italy
Introduction Diseases of the heart valves can be present from birth (congenital valve diseases) or develop throughout l...
Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals
Introduzione La XXII Conferenza Nazionale sulla Farmaceutica, tenutasi a Catania dal 29 febbraio al 1° marzo 2024, ha r...
Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide
Introduzione L’innovazione terapeutica nel contesto del trattamento del virus dell’immunodeficienza umana (HIV), in ter...
D.I.Ri.M.O. project: deprescription, inappropriateness evaluation and therapeutic reconciliation in hospital medicine
Introduction The rising average age of the Italian population and the growing number of patients with multiple health c...
Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy
Introduzione La dermatite atopica (DA) è una malattia infiammatoria cutanea caratterizzata da un decorso cronico e reci...
Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)
Introduction B-cell malignancies are the most common types of blood cancer and encompass over 40 different diseases cau...
Management and utilization of the Fund for Innovative Medicines: a multistakeholder qualitative survey on regional and local practices
Introduzione Il Fondo Farmaci Innovativi (FFI) riveste un ruolo cruciale per finanziare e garantire un accesso rapido a...
Regional tools for the governance of prescribing behaviour and pharmaceutical spending: from literature to concrete experiences and prospects for change
Introduzione Il mercato globale dei farmaci è in costante crescita e se ne prevede un aumento del 5-8% in termini di sp...
Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy
Introduzione Il linfoma anaplastico a grandi cellule sistemico (sALCL) rappresenta una forma rara, severa e aggressiva ...
Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control
Introduction Epilepsy is one of the most common neurological disorders, affecting approximately 50 million people world...
Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data
Introduction Immunoglobulin A nephropathy (IgAN) is a rare disease that, by accumulating IgA-containing immune complexe...
Time to market evaluation for new chemical entities in Italy: a critical analysis of the period 2018-2024
Introduzione In Italia, l’analisi relativa alle tempistiche di autorizzazione delle procedure di prezzo e rimborso dei ...
Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections
Introduction Acute bacterial skin and soft tissue infections (ABSSSIs) are among the most common infections in the gene...
C(nn) and compassionate use: two approaches for early access. Proposals for a better management
Introduzione In Italia, esistono molteplici strumenti regolatori di Early Access Program (EAP), che offrono ai pazienti...
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new...
Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)
Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and p...
The future of drugs distribution in the National Health System
Medaglia, M., Buzzetti, G., Cossolo, M., Deambrosis, P., & Scroccaro, G. (2024). The future of drugs distribution i...
Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis
Robertson I, Leung E, Hughes D, et al. Prospective analysis of stoma-related complications. Colorect...
Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. https://doi.o...
Time to market access in Italy: duration of the P&R process for rare disease drugs
Kwon HY, Kim H, Godman B. Availability and Affordability of Drugs With a Conditional Approval by the...
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy
Cancer.Net. Breast cancer: statistics. https://www.cancer.net/cancer-types/breast-cancer/statistics....
Unmet need: definitions, literature evidence and implications for HTA
Caprari F, Alfano A, Buzzetti G, et al. [Unmet clinical need and new therapeutic options.]. Recenti ...
Good practices for the development of budget impact models at regional level
Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilità e prezzo di u...
COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment
Guidelines for pricing and reimbursement of medicines (determina DG/1372/2020) [Internet]. Agenzia I...
Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members
Preckler V, Espín J. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Polici...
Load More
format_indent_increase